Hims & Hers (HIMS) made a killing last year selling an off-brand version of Ozempic, but with the drug’s shortage now over, ...

Hims & Hers on Monday released fourth-quarter results that disappointed on gross margin and sparked concerns about the future ...

With Hims & Hers' main source of growth set to be extinguished, Citi analysts said its full-year guidance appeared ...

The tech-heavy Nasdaq Composite finished the volatile trading day down around 1.3%, dragged down by shares of Magnificent ...

Here's why TFSA investors should consider holding quality growth stocks such as HIMS and benefit from outsized gains over ...